Close Menu

NEW YORK (GenomeWeb) – MDNA Life Sciences announced today that it has signed an agreement making BL&H the exclusive South Korean distributor of its PCR-based liquid biopsy prostate cancer test, the Prostate Mitomic Test (PMT).

PMT analyzes the mitochondrial genome to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.